Key Takeaways
- • Stada, a German pharmaceuticals group backed by CapVest, is exploring an acquisition of Cooper Consumer Health from CVC Capital Partners at a valuation of approximately €6 billion, according to Bloomberg sources familiar with the matter.
- • Cooper Consumer Health is a diversified consumer health and personal care company with a portfolio spanning hygiene, wellness, and over-the-counter products; the asset may attract competing bids from other private equity buyers.
- • Stada's Chief Executive Peter Goldschmidt signaled earlier in 2026 that the company has capacity to pursue meaningful M&A opportunities across consumer health markets without geographic constraints, positioning this transaction as part of a broader growth strategy.
- • The potential deal reflects improving private equity exit activity in Europe, as sponsors increasingly seek to return capital to investors and monetize portfolio assets in a strengthening market environment.
- • CapVest acquired control of Stada from previous sponsors Bain Capital and Cinven in 2025 for approximately €10 billion including debt, providing the platform with financial flexibility to execute transformational acquisitions.
Summary
German pharmaceutical company Stada is in preliminary discussions to acquire Cooper Consumer Health from private equity owner CVC Capital Partners in a transaction that could value the consumer health business at around €6 billion. The exploration reflects Stada's strategic intent to expand its consumer health footprint following strong recent operational performance and newly available acquisition capacity under current ownership.
Stada itself is backed by CapVest, which acquired control of the company from prior sponsors Bain Capital and Cinven in 2025 in a transaction valued at approximately €10 billion including debt. That recent recapitalization positions Stada with balance sheet flexibility to pursue what Chief Executive Peter Goldschmidt characterized earlier this year as "meaningful M&A opportunities" across consumer health markets. The CEO explicitly stated the company would pursue acquisitions without geographic constraints, signaling ambition to consolidate the fragmented consumer health sector.
Cooper Consumer Health operates across diversified segments within consumer health and personal care, with a branded portfolio spanning hygiene, wellness, and over-the-counter product categories. As a CVC-backed asset, the business has undergone value-creation initiatives typical of private equity ownership. The potential sale would represent a significant exit for CVC, which continues to manage one of Europe's largest alternative asset pools.
The preliminary nature of discussions suggests other bidders may emerge, with the Bloomberg report noting that "the asset may also attract interest from other private equity buyers." This competitive dynamic could influence final valuation, deal structure, and timeline. The transaction would align with a broader trend of improving private equity exit activity across Europe in 2026, as sponsors accelerate portfolio realizations to return capital to limited partners. Such activity signals improving market conditions for monetizing portfolio assets and suggests renewed appetite for pharmaceutical and consumer health M&A among both strategic and financial buyers.
Stada itself is backed by CapVest, which acquired control of the company from prior sponsors Bain Capital and Cinven in 2025 in a transaction valued at approximately €10 billion including debt. That recent recapitalization positions Stada with balance sheet flexibility to pursue what Chief Executive Peter Goldschmidt characterized earlier this year as "meaningful M&A opportunities" across consumer health markets. The CEO explicitly stated the company would pursue acquisitions without geographic constraints, signaling ambition to consolidate the fragmented consumer health sector.
Cooper Consumer Health operates across diversified segments within consumer health and personal care, with a branded portfolio spanning hygiene, wellness, and over-the-counter product categories. As a CVC-backed asset, the business has undergone value-creation initiatives typical of private equity ownership. The potential sale would represent a significant exit for CVC, which continues to manage one of Europe's largest alternative asset pools.
The preliminary nature of discussions suggests other bidders may emerge, with the Bloomberg report noting that "the asset may also attract interest from other private equity buyers." This competitive dynamic could influence final valuation, deal structure, and timeline. The transaction would align with a broader trend of improving private equity exit activity across Europe in 2026, as sponsors accelerate portfolio realizations to return capital to limited partners. Such activity signals improving market conditions for monetizing portfolio assets and suggests renewed appetite for pharmaceutical and consumer health M&A among both strategic and financial buyers.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.